Drug Approval | November 06, 2025
Bayer's finerenone approved in India for heart failure
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Subscribe To Our Newsletter & Stay Updated
